09/09/2026
Today, Kewaunee Scientific Corporation released earnings for its first quarter of fiscal year 2027, ended July 31, 2026.
Highlights for the quarter include sales of $66.3 million, EBITDA of $4.5 million, and an order backlog of $169.0 million.
"I am pleased with Kewaunee's performance during the first quarter and, importantly, with the continued ex*****on of our strategy," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Quoting activity remains strong across our markets, reinforcing our confidence in the underlying demand for our products and capabilities. While project award and release timelines remain extended amid broader geopolitical and economic uncertainty, we continue to see a healthy level of customer activity and opportunity across the business."
"Kewaunee continues to perform well in this environment, strengthening its competitive position and outperforming the broader market, which we believe reflects the strength of our brands, the breadth of our capabilities, and our commitment to delivering exceptional value and service to our customers," Hull continued. "At the same time, we remain disciplined and focused on the areas we can control - serving our customers, improving our operations, strengthening our commercial capabilities, and ensuring we are well positioned as quoting activity converts into project awards and releases."
Read the full release: https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-first-quarter-of-fiscal-year-2027-302874272.html